[Skip to Content]
[Skip to Content Landing]
Viewpoint
August 1, 2017

Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors

Author Affiliations
  • 1Stanford Prevention Research Center, Department of Medicine and Departments of Health Research and Policy, Biomedical Data Science, and Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California
JAMA. 2017;318(5):419-420. doi:10.1001/jama.2017.6765

Evidence for the benefits of cardiovascular prevention, with lifestyle changes or with medications,1 is strong. However, recently released guidelines2-4 from the United States, Europe, and Canada have differing recommendations regarding which patients to treat with medications and whether to tailor treatment aiming for specific targets. Low-density lipoprotein cholesterol (LDL-C) levels are the focal point in this debate.

×